CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells. - Wikidata - wikimedia - TriplyDB

CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells.

CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells.

http://www.wikidata.org/entity/Q37478631

about

Dinosaurs and ancient civilizations: reflections on the treatment of cancer Additive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARs Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms Analysis of tanshinone IIA induced cellular apoptosis in leukemia cells by genome-wide expression profiling.Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and apoptosis resistance induced by Pten deficiency.Identification of novel markers for the diagnosis of malignant pleural mesothelioma.Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells.The interconnectedness of cancer cell signaling.The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells IL-4 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK-pathway and survivin up-regulation.CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms.Silymarin Suppresses Cellular Inflammation By Inducing Reparative Stress Signaling The War on Cancer rages on.Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic.TLR4 activation by lipopolysaccharide confers survival advantage to growth factor deprived prostate cancer cells.INPP4B suppresses prostate cancer cell invasion The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis.p53: key conductor of all anti-acne therapies.Clinical evaluation of macrophages in cancer: role in treatment, modulation and challenges.Bindarit Attenuates Pain and Cancer-Related Inflammation by Influencing Myeloid Cells in a Model of Bone Cancer.Multifaceted Roles for Macrophages in Prostate Cancer Skeletal Metastasis.

P2860

Q24628746-3193E6A7-B716-4EF2-A857-F6A6D8884D7E Q28550672-058C46A9-DA99-4FF3-B4D9-A6BE0DAE0DC0 Q30436152-91144376-D072-4625-9025-DC69B5F80441 Q34128544-D4BC99F0-40BA-419A-9ECD-9E4FD2423CA6 Q34572866-2193F5C3-98CF-4F7E-BE95-CF679709CAC9 Q34760760-CB57FFB8-622C-4045-9E43-4ACD0ABF02A0 Q35095228-6DB822F8-5AB5-4D29-85CD-B9EC0DBB3107 Q35669733-7D9F759D-B0B6-43E8-A254-E7D6F15DBF53 Q35684572-3F890D76-FB93-4D16-A68B-FE3CB4A019B1 Q35914656-FC0A5273-0560-462D-9CE1-C9BBF399AB5C Q36332973-F3A497E0-7D8F-447A-A8DE-64EB4F63C853 Q36435673-EAE6E726-C521-45F5-A9DD-5841322112DF Q37478602-DFE816B6-F099-4E63-BA1F-74F05E426A48 Q37809345-C1A65020-3124-4EFB-A556-D8ADFFB5AD62 Q38892034-F8CB3D41-A9F0-44ED-B799-7C7B8D4BD5F1 Q38953956-A5F2ED51-3086-434C-90B2-AB298F1EB279 Q38970758-5DFC3BB0-2595-4B35-AB59-D6863FBC35DA Q41715894-B6A4A18B-7EDC-4A1E-B1B2-25689050917B Q48290538-4FDF47C4-C47F-4C3E-9232-2B4366AC5DE3 Q49874716-3487E830-B209-478B-920E-D74A19A1F682 Q55364968-45B1AD5D-3549-4C2D-A2C5-C970C9A0AD44

P2860

CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells.

http://www.wikidata.org/entity/Q37478631

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

CCL2 is a negative regulator o ...... man prostate cancer PC3 cells.

@en

CCL2 is a negative regulator o ...... man prostate cancer PC3 cells.

@nl

type

label

CCL2 is a negative regulator o ...... man prostate cancer PC3 cells.

@en

CCL2 is a negative regulator o ...... man prostate cancer PC3 cells.

@nl

prefLabel

CCL2 is a negative regulator o ...... man prostate cancer PC3 cells.

@en

CCL2 is a negative regulator o ...... man prostate cancer PC3 cells.

@nl

P1433

Q37478631-7E9AC904-B92B-47EF-8656-7B41246576AF

P1476

Q37478631-08B123BF-C3C4-48A6-8D62-0918FD257BE6

P2093

Q37478631-62C030A7-8D48-4D35-B03B-1333450E9C5B

Q37478631-B01EAD44-1B07-4BC7-B696-D3F40CB6FDF1

Q37478631-CFA8E822-B4CD-421F-9C36-442112C6828D

P2860

Q37478631-03BF36FF-2148-4444-99A9-05509568CD60

Q37478631-060CE9FE-B763-4927-AB59-E8F8529F9F81

Q37478631-07FD87A3-0C2D-4B73-9B86-97181CBD63F7

Q37478631-087E903E-F1BF-41A3-BE82-18D912005AB7

Q37478631-0B1CB477-0DC6-419F-A40A-C53D29A2DB39

Q37478631-0F423473-1021-40CE-9C03-F7CBCA1894AA

Q37478631-165852BF-08E2-49D0-B494-A25DD09D17D7

Q37478631-21699210-D453-4025-A3CE-F5BB21CDFD08

Q37478631-27F57D68-24D5-4D6F-8852-69CD28D167A4

Q37478631-2CC799C5-4AA8-4736-A94C-7F571870F20F

P304

Q37478631-55F1249D-14D0-45CB-A820-9A90FB63EDC2

P31

Q37478631-F3508C4C-C755-40C8-8471-28701CBF6F1A

P356

Q37478631-F97BAD80-1954-4872-9970-121DE2CC3D68

P433

Q37478631-7659964A-88C5-477F-8DE8-49382B82051F

P478

Q37478631-AD9BEDFB-7B08-49CB-BD6A-05B6C1D50F38

P577

Q37478631-C2D384A1-536E-4771-A17C-EC06456C47EE

P5875

Q37478631-CE317764-2CA7-479E-A294-09CA31AAB6A5

P698

Q37478631-0E28E154-C55E-4281-9F99-DE20E3767682

P932

Q37478631-EAC9A263-A53A-4CC1-A99E-3B614B44F448

P356

P1433

P1476

CCL2 is a negative regulator o ...... man prostate cancer PC3 cells.

@en

P2093

Hernan Roca

http://www.w3.org/2001/XMLSchema#string

Kenneth J Pienta

http://www.w3.org/2001/XMLSchema#string

Zachary S Varsos

http://www.w3.org/2001/XMLSchema#string

P2860

Role of AMP-activated protein kinase in mechanism of metformin action

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

AMPK phosphorylation of raptor mediates a metabolic checkpoint

Identification of a proline-rich Akt substrate as a 14-3-3 binding partner

LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing

The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

Autophagy fights disease through cellular self-digestion

The AMP-activated protein kinase cascade--a unifying system for energy control

P304

1309-1317

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/NEO.09936

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40697131

http://www.w3.org/2001/XMLSchema#string

P698

20019839

http://www.w3.org/2001/XMLSchema#string

P932

2794512

http://www.w3.org/2001/XMLSchema#string